Ukraine: Competition In Ukraine: Feel The 2017 Progress

Ukrainian competition laws and regulatory practice continue to go through the active reform phase and 2017 turned out to be just as busy as 2016, primarily in the sphere of merger control reform. The Antimonopoly Committee of Ukraine (AMC) continues to be the driver of these reforms, implementing best international practices. Most of these reforms have received a warm welcome from the business and professional communities, yet the increase in the average level of fines and constant attempts to test the limits of its jurisdiction combine to make the AMC one of the most powerful governmental agencies, creating concerns for larger businesses regarding compliance risks.

Legislative developments

One of the major novelties for Ukrainian competition lawyers is the introduction of state aid regulations. On 2 August 2017, the Law of Ukraine "On State Aid to Undertakings" (the State Aid Law) entered into force. While the State Aid Law dates back in 2014, giving sufficient time for businesses and the government to become acquainted with the new requirements, it is fair to say that general awareness about state aid legislation, or even a basic understanding of its principles, remains low. This will likely change when enforcement kicks in and the first cases appear on recalling state aid due to misconduct.

When it comes to secondary legislation, the most notable development is the adoption by the AMC in October 2017 of the Vertical Block Exemption Regulation (the Vertical Regulation). This Ukrainian Vertical Regulation is heavily influenced by the Commission Regulation (EU) No 330/2010, providing useful guidance on (i) a block exemption for certain categories of vertical agreements where the absence of an anticompetitive effect may be predicted; and (ii) a list of hardcore and other restrictions falling beyond the scope of the block exemption. More developments are expected in the near future.

In November 2017, a draft law amending procedural rules of case investigation passed a first reading in the Parliament of Ukraine. Among many improvements, this draft law introduces clear deadlines for investigations conducted by the AMC, extends and ensures procedural rights of all parties, improves regulation of the leniency programme, introduces settlement procedures in cartel cases, and provides for other long-awaited changes that shall ensure due process in the AMC's investigations.

Finally, in November 2017 the Parliament of Ukraine adopted a law allowing the AMC to deny merger clearance of transactions involving undertakings featured in the sanctions list. The ambiguous wording of this law raises a lot of issues with applicability to clearances granted and transactions implemented earlier, which will have to be resolved through administrative practice and judicial interpretation.

Hard-hitting precedent: To rebate or not

Throughout 2017, the AMC closely scrutinized various socially important markets. One of the most noticeable investigations concern the pharmaceuticals market. This probe dates back to 2012, focusing on vertical agreements between pharma producers and their distributors. The first fines imposed in 2016 on Alcon and Servier, together with their distributors, were relatively small.

However, on 14 November 2017, the AMC adopted a practice-breaking decision imposing a fine of EUR 2.2 million on Sanofi-Aventis Ukraine (SAU), a subsidiary of French pharma producer Sanofi. Two of its local distributors, Limited Liability Company BADM (BADM) and Limited Liability Company Optima-Pharm Ltd (Optima-Pharm), also received fines of EUR 0.9 million and EUR 1.3 million respectively. This is perhaps the most controversial decision of the AMC in 2017, which demonstrates new approaches and deserves a more detailed look.

Alleged violation

The investigation concerns 2011, when SAU introduced a uniform rebate system for all distributors, with BaDM and Optima-Pharm being the largest among the 10 distributors used by SAU, encouraging them to increase purchase volume and rewarding them for meeting certain targets (volumes, prepayment, stock maintenance, etc.). Similar distribution models were used by other pharmaceutical producers and are also common in other industries.

After five years of investigation, the AMC concluded that the distribution agreements between SAU and each of the distributors resulted in (i) price-setting mechanisms that restrict competition on the markets of Sanofi's pharmaceuticals from cheaper substitutes (market foreclosure); (ii) division of markets according to assortment of goods; and (iii) securing price increase for Sanofi's pharmaceuticals sold through state procurement, which may lead to limitation of competition.

Among the three allegations, market foreclosure is the most interesting one, as it is missing in the cases of Alcon and Servier prosecuted by the AMC in 2016, despite the very similar factual pattern. This is the first case where the AMC used economic analysis to substantiate and develop the "theory of harm". In essence, the allegation is that SAU sold expensive (compared to local substitutes) branded generic pharmaceuticals in high volumes and used rebates to incentivise the distributors to maintain the status quo. The AMC also argued that in SAU's distribution model, rebate points could be earned from all sales, but discounts were applied to products where there was high competition, effectively cross -subsidizing them, while the distributors did not pass on these discounts to their customers, i.e. pharmacies. The AMC ignored the arguments of the parties that there was no evidence of any actual restrictions of competition and no deficit of competing products, because distributors merely responded to demand from consumers and could only sell as much as consumers were willing to buy.

Market definition

In its market analysis, the AMC relied on a very narrow market definition, looking only at substitutes with the same international non-proprietary name (INN), form, and dosage, while completely ignoring substitutability of many pharmaceuticals based on medical protocols or consumer preferences in the case of OTC products. Even the same product with different dosage (e.g. 100 mg and 200 mg) went into two product markets in the AMC probe.

Interestingly, even under the narrowest market definition, there were many product markets on which SAU's market share was small (below 30%, and in some cases even below 5%). However, even in these cases, the AMC did not apply the relevant block exemption permitting vertical conduct and, thus, did not exclude these highly competitive markets from its analysis.

Qualification of violation

It is widely known that rebates and discounts are often investigated by competition authorities within the context of abuse of market power, rather than concerted practices. The EC attempted to shed more light on the lawful application of rebates and discounts in its Guidance on the Commission's enforcement priorities in applying Article [102 TFEU] to abusive exclusionary conduct by dominant undertakings in paragraphs 37 to 45 explaining the circumstances where consumer harm may occur. Violation of these rules may lead to severe prosecution, such as in the Intel case, where a record EUR 1.06 billion fine was imposed for violating Article 102 of the Treaty on the Functioning of the European Union. Even though the use of rebates based on identical terms for all distributors was unilateral conduct of SAU, the AMC decided to qualify such conduct as "concerted practices" between SAU and its distributors, the analogy of EU's Article 101 of the TFEU, because the distributors allegedly benefited from the system by maintaining high prices and keeping a large portion of the resultant profits.

Absence of anticompetitive effects ignored by the AMC

When substantiating the violation, the AMC did not try to show any anticompetitive effects of the alleged "anticompetitive concerted practices" and even ignored any evidence to the contrary. Initially, the AMC assumed that, due to the introduction of rebates, the assortment (i.e. number of SKUs) or volumes of sales of competing products decreased. However, in the face of evidence to the contrary submitted by the parties, in its decision the AMC merely stated that the respective actions "may lead to limitation of competition", without going into actual effects. Given that no negative effects were identified by the AMC five years after the alleged violation, there are serious doubts over whether such conduct really had any impact on competition and could be qualified as "concerted practices" to begin with.

The allegation related to increase of prices in state procurement tenders is also highly controversial. Given that (i) SAU did not participate in any state tenders, (ii) did not distinguish its pricing policy depending on further resale of its products to the public or private sector by the distributors, and (iii) did not influence the pricing policy of its distributors, it is quite difficult to imagine how SAU could influence the prices offered by distributors during a tender, which is a competitive process by definition, and given that no evidence of distortion of any tender was demonstrated.

Lessons from the Sanofi case

The Sanofi case clearly shows that vertical relations present a new risk zone for multinational companies in Ukraine, which was previously underestimated. Even though not all rebates are illegal, off-invoice provision of discounts based on bonus schemes, in the opinion of the AMC, may limit competition from other products. Therefore, any sophisticated commercial conditions other than on-invoice discounts may also come under the scrutiny of the competition agency. Moreover, the low standard of proof and the quality of evidence and economic analysis used by the AMC to support its decision demonstrates a significant increase of prosecution risk, even for companies that adhere to the highest standards in competition law compliance.

Picture the future

The reform of Ukrainian competition laws launched in 2015 is clearly not finished. It is a pleasure to see the increased initiative of the AMC to tackle many issues that were neglected for many years. For example, businesses often need guidance on the approaches to market definition that the AMC uses. This issue is set for clarification in 2018. Some fine-tuning of merger control laws is also on the agenda, including removal of the seller from the calculation of turnover and assets as recommended by the OECD in the most recent peer review. Overall, Ukrainian competition laws are becoming more and more allied with the best practices of other European countries and this should increase the predictability of law enforcement for businesses operating in Ukraine.

Originally published in International directory "Expert Guides".

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions